Shots:
- Japan’s MHLW has approved Shingrix in a PFS format (Recombinant Zoster Vaccine or RSV) for the prevention of shingles (herpes zoster)
- Approval was based on technical comparability between the PFS & existing vaccine presentation; the new presentation does not involve a change in indication or dosing
- Shingrix combines glycoprotein E with the AS01B adjuvant system to enhance immune responses & help protect adults aged ≥50 against shingles despite age-related immune decline
Ref: GSK | Image: GSK | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
